Screener / SEC EDGAR /CIK 0001581280 /10-K filed Nov 17, 2025, compared with Nov 18, 2024 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Twist Bioscience Corp TWST

Compare with peers Embed
Earnings releases

Latest results release: Nov 12, 2026

8-K item 2.02, exhibit 99

What TWST's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

What the company says its adjusted numbers leave out:

Adjusted EBITDA is defined as net income (loss) adjusted to exclude interest income, interest expense, income tax expense, depreciation and amortization, other income/expense, net, stock-based compensation expense, impairment of long-lived assets, and gain on sale of business detailed in the reconciliation table below that we believe are not indicative of our ongoing results. release Aug 4, 2025

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 12, 2026 · EX-99.1

Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2026

Open on SEC

— Record revenue of $459.4 million in Fiscal 2026; Increase of 22% over $376.6 million in Fiscal 2025 —

— Record revenue of $126.6 million in 4QFY26 ; Increase of approximately 28% over $99.0 million in 4QFY25 ; 15th consecutive quarter of sequential growth —

— Gross margin of 52.4% in fiscal 2026 , Improvement of 1.7 margin points versus 50.7% in fiscal 2025 —

— Fiscal 2027 revenue guidance of $550M-$560M, growth of 21% year over year at the midpoint —

— First quarter fiscal 2027 revenue guidance of $130M to $132M, growth of 26% year over year at the midpoint —

(November 12, 2026) — Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value healthcare company, today reported financial results and business highlights for the fourth quarter and full year fiscal 2026 ended September 30, 2026.

“Fiscal 2026 demonstrated what Twist can deliver: strong top line revenue growth, expanded gross margin and positive adjusted EBITDA in the fourth quarter, all while continuing to broaden our capabilities and strengthen our balance sheet," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “We enter fiscal 2027 with a stronger business and the capital to invest in our next phase of growth. AI is expanding what scientists can design, and personalized medicine is increasing the demand for unique molecules. Both play directly to our strength of customization at scale. We are building the infrastructure for where this industry is going, investing in capacity, automation and new products that enable customers to do more with Twist. Our ambition is to make Twist indispensable to the next generation of discovery, diagnostics and therapeutics.”

See "Non-GAAP Information" below and the associated reconciliation table included in this release for a discussion of the measure adjusted EBITDA.

• Revenue: Total revenues for fiscal 2026 grew to $459.4 million compared to $376.6 million for fiscal 2025.

◦ DNA Synthesis and Protein Solutions (DSPS) revenue grew 31.7% to $221.9 million for fiscal 2026 compared to $168.5 million for fiscal 2025.

◦ NGS Applications (NGS) revenue grew 14.1% to $237.5 million for fiscal 2026 compared to $208.1 million for fiscal 2025.

• Cost of Revenues: Cost of revenues for fiscal 2026 was $218.6 million compared to $185.6 million for fiscal 2025.

: Gross margin for fiscal 2026 increased to 52.4% compared to 50.7% for fiscal 2025.

• Research and Development Expenses: Research and development expenses for fiscal 2026 decreased to $71.8 million compared to $80.3 million for fiscal 2025.

• Selling, General and Administrative Expenses: Selling, general and administrative expenses for fiscal 2026 were $301.2 million compared to $247.0 million for fiscal 2025.

• Net Loss: Net loss for fiscal 2026 was $130.2 million, or $2.08 per diluted share, compared to net loss of $77.7 million, or $1.30 per diluted share, for fiscal 2025.

• Adjusted EBITDA: Adjusted EBITDA for fiscal 2026 was $(35.9) million compared to $(46.9) million in fiscal 2025. See the table included in this release for a reconciliation between adjusted EBITDA and net (loss) income attributable to common stockholders, the most directly comparable GAAP financial measure.

Cash Position: As of September 30, 2026, the company had approximately $582 million in cash, cash equivalents and short-term investments .

• Revenue: Total revenues for the fourth quarter of fiscal 2026 grew 28% to $126.6 million compared to $99.0 million for the same period of fiscal 2025.

◦ DNA Synthesis and Protein Solutions (DSPS) revenue grew 33% to $61.0 million for the fourth quarter of fiscal 2026 compared to $46.0 million for the same period of fiscal 2025, and grew 8% sequentially, compared to $56.6 million for the third quarter of fiscal 2026.

◦ NGS Applications (NGS) revenue grew 24% to $65.7 million for the fourth quarter of fiscal 2026 compared to $53.0 million for the same period of fiscal 2025, and grew 6% sequentially, compared to $61.8 million for the third quarter of fiscal 2026.

• Cost of Revenues: Cost of revenues for the fourth quarter of fiscal 2026 increased to $59.4 million compared to $48.2 million for the same period of fiscal 2025.

: Gross margin for the fourth quarter of fiscal 2026 was 53.1%, up from 51.3% for the same period of fiscal 2025.

• Research and Development Expenses: Research and development expenses for the fourth quarter of fiscal 2026 were $17.0 million consistent with $17.0 million for the same period of fiscal 2025.

• Selling, General and Administrative Expenses: Selling, general and administrative expenses for the fourth quarter of fiscal 2026 were $74.7 million compared to $63.8 million for the same period of fiscal 2025.

• Net Loss: Net loss for the fourth quarter of fiscal 2026 decreased to $20.6 million, or $0.32 per diluted share, compared to net loss of $27.1 million, or $0.45 per diluted share, for the same period of fiscal 2025.

• Adjusted EBITDA: Adjusted EBITDA for the fourth quarter of fiscal 2026 was $2.2 million compared to $(7.8) million for the same period of fiscal 2025. See the table included in this release for a reconciliation between adjusted EBITDA and net (loss) income attributable to common stockholders, the most directly comparable GAAP financial measure.

• Shipped products to approximately 4,100 customers in fiscal 2026, versus approximately 3,800 in fiscal 2025.

• Physically shipped approximately 1.3 million genes in fiscal 2026, compared with approximately 938,000 in fiscal 2025.

• Raised net proceeds of approximately $425 million through an equity offering and at-the-market sales.

• Expanded antibody production and characterization portfolio with the launch of Twist Express Screening Antibodies.

• Launched Twist MRD Express, custom panels designed for a rapid turnaround time of as little as one day.

The following statements are based on Twist’s current expectations for fiscal 2027. The following statements are forward-looking, and actual results could differ materially depending on market conditions and the factors set forth under “Forward-Looking Statements” below.

• Total revenue in the range of approximately $550 million to $560 million, growth of approximately 21% year over year at the midpoint.

◦ Initial full year revenue guidance assumes $100 million in revenue for AI drug discovery and sequential growth across both DNA Synthesis and Protein Solutions and NGS Applications

• Capital expenditures of approximately $75 million as part of our two-year investment plan, excluding landlord-funded tenant improvements

• Total revenue of approximately $130 million to $132 million, growth of approximately 26% year over year at the midpoint and continued sequential growth

This release includes adjusted EBITDA, which is a non-GAAP financial measure, for the periods presented. Adjusted EBITDA is defined as net (loss) income adjusted to exclude interest income, income tax expense, depreciation and amortization, litigation settlement costs, net of recoveries, gain on sale of business, other income/expense, net, and stock-based compensation expense. This non-GAAP measure is not in accordance with, or an alternative for, measures prepared in accordance with generally accepted accounting principles (GAAP) and may be different from non-GAAP measures used by other companies. In addition, this non-GAAP measure is not based on any comprehensive set of accounting rules or principles. We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors’ and analysts’ ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. However, non-GAAP information is not superior to financial measures calculated in accordance with GAAP, is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. A reconciliation table of the most comparable GAAP financial measure to the non-GAAP financial measure is included at the end of this press release.

A reconciliation of adjusted EBITDA for the full year fiscal 2027 to a corresponding GAAP financial guidance measure is not available on a forward- looking basis because the Company does not provide guidance on GAAP net (loss) income and is not able to present the various reconciling cash and non-cash items between GAAP net (loss) income and adjusted EBITDA without unreasonable effort. In particular, stock-based compensation expense is impacted by the Company’s future hiring and retention needs, as well as the future fair market value of its common stock, all of which is difficult to predict and is subject to change. The actual amount of these expenses during the full year fiscal 2027 will have a significant impact on Twist’s future GAAP financial results.

The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss its financial results and provide an update on the company’s business. The conference call will be webcast live through the Investor Relations section under the “Company” tab at www.twistbioscience.com. Those parties interested in participating via telephone must register on the Company’s Investor Relations website or by clicking here. Upon registration, all telephone participants will receive the dial-in number along

with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks.

At Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets.

We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal – more experiments, more iterations, more chances for remarkable discoveries.

Together, we stand with customers in the relentless pursuit of progress, backed by enterprise reliability, to shape a healthier and more sustainable future for all. For more information about our products and services, please visit www.twistbioscience.com .

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, projections under the heading “Fiscal 2027 Financial Guidance” and the assumptions underlying that guidance, statements regarding future growth and expansion in future fiscal periods, including fiscal 2027, long-term financial targets and objectives, including statements regarding our revenue growth trajectory, drivers of future revenue and gross margin growth, including expected growth of AI-enabled discovery, nucleic acid therapeutics and molecular residual disease applications planned capital expenditures, expected manufacturing capacity, planned expansion of protein expression and characterization capacity, estimated annual revenues, ability and timing to achieve profitability, ability to maintain adjusted EBITDA breakeven and ability to maintain or increase gross margins and Twist’s other expectations regarding its future operations plans and financial performance, introduction of new products, and newly announced partnerships. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the

ability to attract new customers and retain and grow sales from existing customers; the ability to sustain demand from customers pursuing AI-enabled drug discover and the risk that such demand may not continue at current rates; the ability to expand manufacturing capacity; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in the life sciences industry that could make the products and services Twist is developing obsolete or non-competitive; the ability to integrate and leverage artificial intelligence and machine learning technologies to improve operational efficiency, product development, and customer solutions; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist’s costs and delay commercialization efforts; changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; the ability to maintain and enforce intellectual property protection; uncertainty as to economic and market conditions and the impact of adverse economic conditions; and the ability to obtain financing when necessary. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist’s business in general, see Twist’s risk factors set forth in Twist’s Annual Report on Form 10-K expected to be filed with the Securities and Exchange Commission on November 16, 2026 . Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

September 30, September 30, (In thousands) 2026 2025 ────────────────────────────────────────────────────────────────────────────── Assets Current assets: Cash and cash $ 533,992 $ 183,049 equivalents Short-term investments 47,915 49,385 Accounts receivable, 70,194 57,019 net Inventories 46,411 28,309 Prepaid expenses and other current 38,712 15,204 assets Total current assets $ 737,224 $ 332,966 Property and 122,323 102,283 equipment, net Operating lease 69,277 49,377 right-of-use assets Investment in equity 68,087 54,337 securities Other non-current 124,897 102,898 assets Total assets $ 1,121,808 $ 641,861 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 24,850 $ 11,094 Accrued compensation 38,318 31,288 Current portion of operating lease 8,448 13,822 liability Accrued expenses and other current 54,194 35,202 liabilities Total current $ 125,810 $ 91,406 liabilities Operating lease liability, net of 86,537 61,750 current portion Liability related to the sale of future 15,000 15,000 revenue Other non-current 6,445 747 liabilities Total liabilities $ 233,792 $ 168,903 Total stockholders’ $ 888,016 $ 472,958 equity Total liabilities and stockholders’ $ 1,121,808 $ 641,861 equity

(in thousands) The following table sets forth a reconciliation between our Adjusted EBITDA and net loss, the most directly comparable GAAP financial measure, for each of the periods presented:

Full text with the tables
                                                                                
  Exhibit 99.1                                                                  
                                                                                
    Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2026    
                                                                                
                               Financial Results                                
                                                                                
 — Record revenue of $459.4 million in Fiscal 2026; Increase of 22% over $376.6 
                            million in Fiscal 2025 —                            
                                                                                
  — Record revenue of $126.6 million in 4QFY26 ; Increase of approximately 28%  
 over $99.0 million in 4QFY25 ; 15th consecutive quarter of sequential growth — 
                                                                                
— Gross margin of 52.4% in fiscal 2026 , Improvement of 1.7 margin points versus
                             50.7% in fiscal 2025 —                             
                                                                                
 — Fiscal 2027 revenue guidance of $550M-$560M, growth of 21% year over year at 
                                 the midpoint —                                 
                                                                                
 — First quarter fiscal 2027 revenue guidance of $130M to $132M, growth of 26%  
                        year over year at the midpoint —                        
                                                                                
  SOUTH SAN FRANCISCO, Calif. --                                                
                                                                                
(November 12, 2026) — Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap
growth and value healthcare company, today reported financial results and
business highlights for the fourth quarter and full year fiscal 2026 ended
September 30, 2026.

“Fiscal 2026 demonstrated what Twist can deliver: strong top line revenue
growth, expanded gross margin and positive adjusted EBITDA in the fourth
quarter, all while continuing to broaden our capabilities and strengthen our
balance sheet," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist
Bioscience. “We enter fiscal 2027 with a stronger business and the capital to
invest in our next phase of growth. AI is expanding what scientists can design,
and personalized medicine is increasing the demand for unique molecules. Both
play directly to our strength of customization at scale. We are building the
infrastructure for where this industry is going, investing in capacity,
automation and new products that enable customers to do more with Twist. Our
ambition is to make Twist indispensable to the next generation of discovery,
diagnostics and therapeutics.”

See "Non-GAAP Information" below and the associated reconciliation table
included in this release for a discussion of the measure adjusted EBITDA.
                                                                                
  FISCAL 2026 FINANCIAL RESULTS                                                 
                                                                                
• Revenue: Total revenues for fiscal 2026 grew to $459.4 million compared to
$376.6 million for fiscal 2025.

◦ DNA Synthesis and Protein Solutions (DSPS) revenue grew 31.7% to $221.9
million for fiscal 2026 compared to $168.5 million for fiscal 2025.

◦ NGS Applications (NGS) revenue grew 14.1% to $237.5 million for fiscal 2026
compared to $208.1 million for fiscal 2025.

• Cost of Revenues: Cost of revenues for fiscal 2026 was $218.6 million compared
to $185.6 million for fiscal 2025.

•
                                                                                
  Gross Margin                                                                  
                                                                                
: Gross margin for fiscal 2026 increased to 52.4% compared to 50.7% for fiscal
2025.

• Research and Development Expenses: Research and development expenses for
fiscal 2026 decreased to $71.8 million compared to $80.3 million for fiscal
2025.

• Selling, General and Administrative Expenses: Selling, general and
administrative expenses for fiscal 2026 were $301.2 million compared to $247.0
million for fiscal 2025.

• Net Loss: Net loss for fiscal 2026 was $130.2 million, or $2.08 per diluted
share, compared to net loss of $77.7 million, or $1.30 per diluted share, for
fiscal 2025.

• Adjusted EBITDA: Adjusted EBITDA for fiscal 2026 was $(35.9) million compared
to $(46.9) million in fiscal 2025. See the table included in this release for a
reconciliation between adjusted EBITDA and net (loss) income attributable to
common stockholders, the most directly comparable GAAP financial measure.
                                                                                
  •                                                                             
                                                                                
Cash Position: As of September 30, 2026, the company had approximately $582
million in cash, cash equivalents and short-term investments .
                                                                                
  FISCAL 2026 FOURTH QUARTER FINANCIAL RESULTS                                  
                                                                                
• Revenue: Total revenues for the fourth quarter of fiscal 2026 grew 28% to
$126.6 million compared to $99.0 million for the same period of fiscal 2025.

◦ DNA Synthesis and Protein Solutions (DSPS) revenue grew 33% to $61.0 million
for the fourth quarter of fiscal 2026 compared to $46.0 million for the same
period of fiscal 2025, and grew 8% sequentially, compared to $56.6 million for
the third quarter of fiscal 2026.

◦ NGS Applications (NGS) revenue grew 24% to $65.7 million for the fourth
quarter of fiscal 2026 compared to $53.0 million for the same period of fiscal
2025, and grew 6% sequentially, compared to $61.8 million for the third quarter
of fiscal 2026.

• Cost of Revenues: Cost of revenues for the fourth quarter of fiscal 2026
increased to $59.4 million compared to $48.2 million for the same period of
fiscal 2025.

•
                                                                                
  Gross Margin                                                                  
                                                                                
: Gross margin for the fourth quarter of fiscal 2026 was 53.1%, up from 51.3%
for the same period of fiscal 2025.

• Research and Development Expenses: Research and development expenses for the
fourth quarter of fiscal 2026 were $17.0 million consistent with $17.0 million
for the same period of fiscal 2025.

• Selling, General and Administrative Expenses: Selling, general and
administrative expenses for the fourth quarter of fiscal 2026 were $74.7 million
compared to $63.8 million for the same period of fiscal 2025.

• Net Loss: Net loss for the fourth quarter of fiscal 2026 decreased to $20.6
million, or $0.32 per diluted share, compared to net loss of $27.1 million, or
$0.45 per diluted share, for the same period of fiscal 2025.

• Adjusted EBITDA: Adjusted EBITDA for the fourth quarter of fiscal 2026 was
$2.2 million compared to $(7.8) million for the same period of fiscal 2025. See
the table included in this release for a reconciliation between adjusted EBITDA
and net (loss) income attributable to common stockholders, the most directly
comparable GAAP financial measure.

Recent Highlights:

• Shipped products to approximately 4,100 customers in fiscal 2026, versus
approximately 3,800 in fiscal 2025.

• Physically shipped approximately 1.3 million genes in fiscal 2026, compared
with approximately 938,000 in fiscal 2025.

• Raised net proceeds of approximately $425 million through an equity offering
and at-the-market sales.

• Joined Lilly TuneLab as a provider of antibody characterization services.

• Expanded antibody production and characterization portfolio with the launch of
Twist Express Screening Antibodies.

• Launched Twist MRD Express, custom panels designed for a rapid turnaround time
of as little as one day.
                                                                                
  Fiscal 2027 Financial Guidance                                                
                                                                                
The following statements are based on Twist’s current expectations for fiscal
2027. The following statements are forward-looking, and actual results could
differ materially depending on market conditions and the factors set forth under
“Forward-Looking Statements” below.

For the full fiscal year 2027, Twist expects:

• Total revenue in the range of approximately $550 million to $560 million,
growth of approximately 21% year over year at the midpoint.

◦ Initial full year revenue guidance assumes $100 million in revenue for AI drug
discovery and sequential growth across both DNA Synthesis and Protein Solutions
and NGS Applications

• Gross margin of approximately 52.5% to 53%.

• Adjusted EBITDA positive

• Capital expenditures of approximately $75 million as part of our two-year
investment plan, excluding landlord-funded tenant improvements

For the first quarter of fiscal 2027, Twist expects:

• Total revenue of approximately $130 million to $132 million, growth of
approximately 26% year over year at the midpoint and continued sequential growth
                                                                                
  Non-GAAP Information                                                          
                                                                                
This release includes adjusted EBITDA, which is a non-GAAP financial measure,
for the periods presented. Adjusted EBITDA is defined as net (loss) income
adjusted to exclude interest income, income tax expense, depreciation and
amortization, litigation settlement costs, net of recoveries, gain on sale of
business, other income/expense, net, and stock-based compensation expense. This
non-GAAP measure is not in accordance with, or an alternative for, measures
prepared in accordance with generally accepted accounting principles (GAAP) and
may be different from non-GAAP measures used by other companies. In addition,
this non-GAAP measure is not based on any comprehensive set of accounting rules
or principles. We believe that this non-GAAP financial measure, when considered
together with our financial information prepared in accordance with GAAP, can
enhance investors’ and analysts’ ability to meaningfully compare our results
from period to period and to our forward-looking guidance, and to identify
operating trends in our business. However, non-GAAP information is not superior
to financial measures calculated in accordance with GAAP, is presented for
supplemental informational purposes only, has limitations as an analytical tool
and should not be considered in isolation or as a substitute for financial
information presented in accordance with GAAP. A reconciliation table of the
most comparable GAAP financial measure to the non-GAAP financial measure is
included at the end of this press release.

A reconciliation of adjusted EBITDA for the full year fiscal 2027 to a
corresponding GAAP financial guidance measure is not available on a forward-
looking basis because the Company does not provide guidance on GAAP net (loss)
income and is not able to present the various reconciling cash and non-cash
items between GAAP net (loss) income and adjusted EBITDA without unreasonable
effort. In particular, stock-based compensation expense is impacted by the
Company’s future hiring and retention needs, as well as the future fair market
value of its common stock, all of which is difficult to predict and is subject
to change. The actual amount of these expenses during the full year fiscal 2027
will have a significant impact on Twist’s future GAAP financial results.
                                                                                
  Conference Call Information                                                   
                                                                                
The company plans to hold a conference call and live audio webcast for analysts
and investors at 8:00 a.m. Eastern Time today to discuss its financial results
and provide an update on the company’s business. The conference call will be
webcast live through the Investor Relations section under the “Company” tab at
www.twistbioscience.com. Those parties interested in participating via telephone
must register on the Company’s Investor Relations website or by clicking here.
Upon registration, all telephone participants will receive the dial-in number
along

with a unique PIN number that can be used to access the call. To avoid delays,
we encourage participants to dial into the conference call fifteen minutes ahead
of the scheduled start time. The webcast replay will be available for two weeks.
                                                                                
  About Twist Bioscience                                                        
                                                                                
At Twist Bioscience, our customizable solutions across the biological continuum
raise the bar in diagnostics, therapeutics, industrial, agriculture and research
markets.

We drive innovation with confidence, without compromise. Whether delivering
oligos, genes, proteins, libraries, characterization data, antibody discovery
solutions, or NGS workflow tools, our scientific expertise and exceptional
customer experience help navigate complex challenges, all with precision and at
the scale and speed customers require. By enhancing R&D efficiency at every
turn, we give scientists more shots on goal – more experiments, more iterations,
more chances for remarkable discoveries.

Together, we stand with customers in the relentless pursuit of progress, backed
by enterprise reliability, to shape a healthier and more sustainable future for
all. For more information about our products and services, please visit
www.twistbioscience.com .

Follow us on LinkedIn | X | YouTube | Instagram | Bluesky
                                                                                
  Legal Notice Regarding Forward-Looking Statements                             
                                                                                
This press release contains forward-looking statements. All statements other
than statements of historical facts contained herein are forward-looking
statements reflecting the current beliefs and expectations of management made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, including, but not limited to, projections under the heading
“Fiscal 2027 Financial Guidance” and the assumptions underlying that guidance,
statements regarding future growth and expansion in future fiscal periods,
including fiscal 2027, long-term financial targets and objectives, including
statements regarding our revenue growth trajectory, drivers of future revenue
and gross margin growth, including expected growth of AI-enabled discovery,
nucleic acid therapeutics and molecular residual disease applications planned
capital expenditures, expected manufacturing capacity, planned expansion of
protein expression and characterization capacity, estimated annual revenues,
ability and timing to achieve profitability, ability to maintain adjusted EBITDA
breakeven and ability to maintain or increase gross margins and Twist’s other
expectations regarding its future operations plans and financial performance,
introduction of new products, and newly announced partnerships. Forward-looking
statements involve known and unknown risks, uncertainties, and other important
factors that may cause Twist’s actual results, performance, or achievements to
be materially different from any future results, performance, or achievements
expressed or implied by the forward-looking statements. Such risks and
uncertainties include, among others, the

ability to attract new customers and retain and grow sales from existing
customers; the ability to sustain demand from customers pursuing AI-enabled drug
discover and the risk that such demand may not continue at current rates; the
ability to expand manufacturing capacity; the ability of Twist to achieve
sufficient revenue to achieve or maintain positive cash flow from operations or
profitability in any given period; risks and uncertainties of rapidly changing
technologies and extensive competition in the life sciences industry that could
make the products and services Twist is developing obsolete or non-competitive;
the ability to integrate and leverage artificial intelligence and machine
learning technologies to improve operational efficiency, product development,
and customer solutions; dependence on one supplier for a critical component;
dependence on key personnel; additional regulations that could increase Twist’s
costs and delay commercialization efforts; changes in U.S. trade policies and
other trade actions that could result in increased costs and supply chain
disruptions; the ability to maintain and enforce intellectual property
protection; uncertainty as to economic and market conditions and the impact of
adverse economic conditions; and the ability to obtain financing when necessary.
For a description of the risks and uncertainties that could cause actual results
to differ from those expressed in these forward-looking statements, as well as
risks relating to Twist’s business in general, see Twist’s risk factors set
forth in Twist’s Annual Report on Form 10-K expected to be filed with the
Securities and Exchange Commission on November 16, 2026 . Any forward-looking
statements contained in this press release speak only as of the date hereof, and
Twist specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or otherwise.

For Investors:

Angela Bitting

SVP, Corporate Affairs

925-202-6211

[email protected]

For Media:

Amanda Houlihan

Communications Manager

774-265-5334

[email protected]
                                                                                
                          Twist Bioscience Corporation                          
                                                                                
                                                                                
                Condensed Consolidated Statements of Operations                 
                                                                                
                                  (Unaudited)                                   
                                                                                
                                 (in thousands)                                 
                                                                                
  (…                                                                            
  t…          Th…                                  Tw…                          
  e…          mo…                                  mo…                          
  p…          en…                                  en…                          
  s…          Se…                                  Se…                          
  d…    2026  30,          20…               2026  30,          20…             
 ────────────────────────────────────────────────────────────────────────────── 
  R…    $     12…          $    99,…         $     45…          $    376…       
  C…                                                                            
  a…                                                                            
  e…                                                                            
  C…                                                                            
  of    $     59…          $    48,…         $     21…          $    185…       
  r…                                                                            
  R…                                                                            
  a…               16,…               17…               71,…               80…  
  d…                                                                            
  e…                                                                            
  S…                                                                            
  g…                                                                            
  a…               74,…               63…               301…               24…  
  a…                                                                            
  e…                                                                            
  L…                                                                            
  s…                                                                            
  c…            —                  —               7,…                  —       
  n…                                                                            
  of                                                                            
  r…                                                                            
  T…                                                                            
  c…    $     15…          $    128…         $     59…          $    512…       
  a…                                                                            
  e…                                                                            
  L…                                                                            
  f…    $     -2…          $    -29…         $     -1…          $    -13…       
  o…                                                                            
  G…                                                                            
  on                                                                            
  s…    $       —          $       —         $       —          $    48,…       
  of                                                                            
  b…                                                                            
  I…               3,4…               2,…               8,8…               11…  
  i…                                                                            
  O…                                                                            
  i…                170               420                856               -9…  
  (…                                                                            
  n…                                                                            
  I…                                                                            
  t…                201               -2…               -406               -7…  
  e…                                                                            
  N…    $     -2…          $    -27…         $     -1…          $    -77…       
  l…                                                                            
  N…                                                                            
  (…                                                                            
  i…                                                                            
  p…    $     -0…          $    -0.…         $     -2…          $    -1.…       
  s…                                                                            
  —                                                                             
  b…                                                                            
  W…                                                                            
  a…                                                                            
  s…                                                                            
  u…                                                                            
  in                                                                            
  c…                                                                            
  n…               65,…               60…               62,…               59…  
  (…                                                                            
  i…                                                                            
  p…                                                                            
  s…                                                                            
  —                                                                             
  b…                                                                            
  N…                                                                            
  (…                                                                            
  i…                                                                            
  p…    $     -0…          $    -0.…         $     -2…          $    -1.…       
  s…                                                                            
  —                                                                             
  d…                                                                            
  W…                                                                            
  a…                                                                            
  s…                                                                            
  u…                                                                            
  in                                                                            
  c…               65,…               60…               62,…               59…  
  n…                                                                            
  (…                                                                            
  i…                                                                            
  p…                                                                            
  s…                                                                            
  —…                                                                            
                                                                                
                                                                                
                          Twist Bioscience Corporation                          
                                                                                
                                                                                
                     Condensed Consolidated Balance Sheets                      
                                                                                
                                  (Unaudited)                                   
                                                                                
                                 (in thousands)                                 
                                                                                
                                             September 30,       September 30,  
                          (In thousands)              2026                2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Assets                                                                        
  Current assets:                                                               
  Cash and cash                           $        533,992    $        183,049  
  equivalents                                                                   
  Short-term investments                            47,915              49,385  
  Accounts receivable,                              70,194              57,019  
  net                                                                           
  Inventories                                       46,411              28,309  
  Prepaid expenses and                                                          
  other current                                     38,712              15,204  
  assets                                                                        
  Total current assets                    $        737,224    $        332,966  
  Property and                                     122,323             102,283  
  equipment, net                                                                
  Operating lease                                   69,277              49,377  
  right-of-use assets                                                           
  Investment in equity                              68,087              54,337  
  securities                                                                    
  Other non-current                                124,897             102,898  
  assets                                                                        
  Total assets                            $      1,121,808    $        641,861  
  Liabilities and                                                               
  stockholders’ equity                                                          
  Current liabilities:                                                          
  Accounts payable                        $         24,850    $         11,094  
  Accrued compensation                              38,318              31,288  
  Current portion of                                                            
  operating lease                                    8,448              13,822  
  liability                                                                     
  Accrued expenses and                                                          
  other current                                     54,194              35,202  
  liabilities                                                                   
  Total current                           $        125,810    $         91,406  
  liabilities                                                                   
  Operating lease                                                               
  liability, net of                                 86,537              61,750  
  current portion                                                               
  Liability related to                                                          
  the sale of future                                15,000              15,000  
  revenue                                                                       
  Other non-current                                  6,445                 747  
  liabilities                                                                   
  Total liabilities                       $        233,792    $        168,903  
  Total stockholders’                     $        888,016    $        472,958  
  equity                                                                        
  Total liabilities and                                                         
  stockholders’                           $      1,121,808    $        641,861  
  equity                                                                        
                                                                                
                                                                                
                          Twist Bioscience Corporation                          
                                                                                
                                                                                
                                Adjusted EBITDA                                 
                                                                                
                                  (Unaudited)                                   
                                                                                
                                 (in thousands)                                 
The following table sets forth a reconciliation between our Adjusted EBITDA and
net loss, the most directly comparable GAAP financial measure, for each of the
periods presented:
                                                                                
          Three                             Twel…                               
          mont…                             mont…                               
          ended                             ended                               
          Sept…                             Sept…                               
  (In     30,                               30,                                 
  tho…    2026              2025            2026             2025               
 ────────────────────────────────────────────────────────────────────────────── 
  Net     $        -20,…    $       -27…    $        -13…    $            -77…  
  loss                                                                          
  Add                                                                           
  (De…                                                                          
  adj…                                                                          
  Int…    $        -3,4…    $       -2,…    $        -8,…    $            -11…  
  inc…                                                                          
  Inc…                                                                          
  tax               -201             256              406                  719  
  exp…                                                                          
  Dep…                                                                          
  and              7,096            6,0…             26,…                 24,…  
  amo…                                                                          
  EBI…    $        -17,…    $       -23…    $        -11…    $            -63…  
  Add                                                                           
  (De…                                                                          
  adj…                                                                          
  Lit…                                                                          
  set…                                                                          
  cos…    $            —    $          —    $        7,2…    $               —  
  net                                                                           
  of                                                                            
  rec…                                                                          
  Gain                                                                          
  on                                                                            
  sale                 —               —                —          -48,…        
  of                                                                            
  bus…                                                                          
  Oth…                                                                          
  (in…              -170            -420             -856            903        
  exp…                                                                          
  net                                                                           
  Sto…                                                                          
  com…             19,4…            16,…             69,…                 64,…  
  exp…                                                                          
  Adj…    $        2,155    $       -7,…    $        -35…    $            -46…  
  EBI…                                                                          
                                                                                

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TWST/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.